The Federal Register document behind the headlines — what it says, what it does not say, and the November 13 comment deadline.
Published November 7, 2026. Primary source: Federal Register, Vol. 91, pp. 68526–68527 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496).
The headline you have seen — and what the document actually is
In the last two weeks you have probably seen some version of “peptides are legal now” or “six peptides approved by prescription.” Here is what actually happened, from the document itself.
On October 30, 2026, the Department of Health and Human Services published an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. It was signed by Secretary Robert F. Kennedy Jr. The policy states, in its own words, that it “does not establish any rights for any person and is not binding on HHS or the public” — and reminds readers that compounded drugs are not FDA-approved.
What the policy does
HHS states it does not intend to take enforcement action against state-licensed 503A pharmacies, federal facilities, or licensed physicians compounding six peptides — BPC-157 (acetate), TB-500 (acetate), MOTS-c (acetate), epitalon (acetate), semax (free base), and KPV (acetate) — in specified forms and routes only, single-ingredient products only, for patient-specific prescriptions, if all ten of its conditions are met. Those conditions include: bulk substance from an FDA-registered (Section 510) facility with a valid certificate of analysis meeting FDA criteria; MedWatch and state-board reporting of products, serious adverse events and quality problems; “compounded drug product — not for resale” labeling; and a 510(k)-cleared syringe where applicable. Oral forms need documentation of adequate human absorption.
What it does not do — the four distinctions that matter
- Discretion ≠ approval. None of the six is FDA-approved. The policy changes enforcement posture, not approval status.
- Discretion ≠ the Bulks List. Nothing was added to the 503A Bulks List (21 CFR 216.23 is unchanged). The July 2026 PCAC votes recommending these substances (BPC-157 8–6, TB-500 8–6, KPV 8–6, MOTS-c 7–5, epitalon 7–4, semax 8–5 — over unanimous FDA staff opposition) remain recommendations until rulemaking finishes, possibly 2027–2028.
- Blends are not covered. Stacks — Wolverine, GLOW, KLOW — are combinations. The policy reaches single-ingredient products only. A “Wolverine vial” is outside it by definition.
- States are not bound. A state board of pharmacy or medicine can keep its own line. Alabama barred its licensees from non-approved peptides in June 2026; Ohio has suspended 30+ clinics since early 2025. Expect permissive states (TX, FL, NV, AZ) and restrictive states to diverge — availability by prescription is a state-by-state fact.
The week that followed (the commercial wave)
- Nov 2 — LegitScript updated its certification review, opening advertising and payment rails for compliant telehealth offers.
- Nov 3 — USP objected: the six have no USP-NF monographs, no USP reference standards, and no established USAN names, so quality “cannot be reliably and consistently established” by the referenced standards alone.
- Nov 5 — Amble Health and The Precision Peptide Company launched all six; Superpower had already opened clinician-prescribed preorders (BPC-157 $149/mo, TB-500 $149/mo, MOTS-c $199/mo; ship target late November). Creator headlines followed — some careful, some (“temporarily approved”) not. The gap between headline and document is why this page exists.
The live deadline
Public comments close November 13, 2026, 11:59 PM ET — Docket HHS-OASH-2026-0496. A patient-safety group’s citizen petition and an industry association’s request for a pause are also on file. Whatever you think of the policy, the docket is where the record is being made this week.
Where the “seven” came from
Seven substances were evaluated at the July PCAC meeting. Six were recommended; the seventh — emideltide (DSIP) — was rejected 6–7 and is not in the policy. If you heard “seven peptides by prescription,” you heard the evaluation count, not the outcome.
Educational information only — not medical or legal advice. Status as of November 7, 2026. See Our Legal Mandate.